Going Concern and Managements Liquidity Plans	3 Months Ended
Mar. 31, 2024
Substantial Doubt About Going Concern [Abstract]
Going Concern and Managements Liquidity Plans	NOTE 4 — GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The Company’s liquidity needs historically have been satisfied through debt and equity financing. As of March 31, 2024, the Company had cash of $892,161 and an accumulated deficit of $61,774,360. In addition, the Company had a net loss from continuing operations of $3,553,162 and negative cash flows from operations of $1,075,778 for the three months ended March 31, 2024. Due to its current liabilities and other potential liabilities, the cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these financial statements are available for issuance. The Company may need to raise additional capital through equity or debt issuances. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations and reducing payroll expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. In April 2024, the Company sold 1,331,452 shares of its Common Stock for gross proceeds of $3,001,235 (see Note 15 - Subsequent Events). In addition, the Company has refocused its efforts on aesthetic products that have near-term commercial potential, reprioritized its research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize. The Company is also exploring out-licensing of certain research and development programs to generate non-dilutive liquidity.

Going Concern and Managements Liquidity Plans

3 Months Ended

Mar. 31, 2024

Substantial Doubt About Going Concern [Abstract]

Going Concern and Managements Liquidity Plans

NOTE 4 — GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

The Company’s liquidity needs historically have been satisfied through debt and equity financing. As of March 31, 2024, the Company had cash of $892,161 and an accumulated deficit of $61,774,360. In addition, the Company had a net loss from continuing operations of $3,553,162 and negative cash flows from operations of $1,075,778 for the three months ended March 31, 2024.

Due to its current liabilities and other potential liabilities, the cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these financial statements are available for issuance. The Company may need to raise additional capital through equity or debt issuances. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations and reducing payroll expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

In April 2024, the Company sold 1,331,452 shares of its Common Stock for gross proceeds of $3,001,235 (see Note 15 - Subsequent Events). In addition, the Company has refocused its efforts on aesthetic products that have near-term commercial potential, reprioritized its research and development, and ceased clinical studies of product candidates that will take more than a year to commercialize. The Company is also exploring out-licensing of certain research and development programs to generate non-dilutive liquidity.